NCT05324124

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

An Open-Label, Randomized, Two-Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of Selpercatinib in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Loxo Oncology, Inc. · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to learn about how food affects selpercatinib in healthy participants. The selpercatinib will be administered in fed and fasted states. Participation could last about 7 weeks.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Selpercatinib	Administered orally.

Timeline

• Start date: 2022-04-19
• Primary completion: 2022-06-22
• Completion: 2022-06-22
• First posted: 2022-04-12
• Last updated: 2025-03-21
• Results posted: 2025-03-21

Locations

1 site across 1 country: Singapore

Regulatory

• FDA-regulated drug study